Who published this market news?

TradingView published this market news item.

Syndax to unveil new pipeline assets, targets INDs for SNDX-4321 and SNDX-62122

Syndax highlighted late-stage programs and unveiled two new pipeline assets—SNDX-4321 (allosteric EGFR inhibitor) and SNDX-62122 (next-gen menin inhibitor)—and set IND/timeline targets for both.Key Highlights:Original SEC Filing: Syndax Pharmaceuticals Inc [ SNDX ] - 8-K - Jul. 14, 2026This is an A…

Syndax highlighted late-stage programs and unveiled two new pipeline assets—SNDX-4321 (allosteric EGFR inhibitor) and SNDX-62122 (next-gen menin inhibitor)—and set IND/timeline targets for both.

Key Highlights:

Syndax unveiled SNDX-4321, a mutant-selective allosteric EGFR inhibitor for EGFRm NSCLC; IND aimed by YE 2026, Ph1 in 2027.
SNDX-62122, first wholly owned next-gen menin inhibitor, selected for myelofibrosis; IND and Ph1 targeted in 2027, leveraging revumenib data.
Phase 2 axatilimab trial in IPF remains on track for topline data in 4Q26; Ph2 axatilimab + rux data also expected 4Q26.
Revumenib proof-of-principle MF trial to start in 4Q26 with initial clinical data anticipated in 2H27 to de-risk next-gen menin programs.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.